Adam Simpson, Icosavax CEO
December 14, 2022 10:52 AM ESTUpdated 11:11 AM
R&D

Icosavax push­es for­ward with an RSV can­di­date af­ter Covid-19 vac­cine flop

Tyler Patchen

News Reporter

Seat­tle-based Icosavax was at­tempt­ing to make a splash ear­li­er this year by show­ing off da­ta for its Covid-19 vac­cine can­di­date, but it end­ed up hit­ting …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times